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SUBPLANTAR injection of Pilocarpus spicatus essential oil
(PSEO), induced rat hindpaw oedema in a dose-dependent
manner. The time course study revealed that when com-
pared to carrageenan-induced oedema, the oedema re-
sponse to PSEO was greater at 1 h post-injection, and
thereafter remained relatively constant until 5 h post-injec-
tion. By 24 h, it was still at almost the 50% level. This
effect of PSEO was characterized using several inhibitors
of oedema formation. Pretreatment with the Hi-receptor
antagonist chlorpheniramine did not affect this response,
while a significant reduction ofpaw oedema was achieved
with the serotonin antagonist methysergide, but only 1 h
and 2 h after injection ofPSEO. The oedemagenic activity
of PSEO was also suppressed by pretreating the rats with
the eicosanoid synthesis inhibitors, phenylbutazone, EP
10161 and dexamethasone. This last drug showed the
greatest potency. These findings suggested a probable
injury to dermal mast cells and liberation of arachidonate
metabolites and eicosanoids at the late phase of oedema
induced by PSEO.
Key words: Eicosanoids, essential oil, Pilocarpus spicatus, rat
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Introduction
Experimental acute inflammation can be pro-
duced by subplantar injection of a number of
irritant substances in the hindpaw of rat. Among
those of special interest is carrageenan, a sulphated
saccharide derived from the red seaweed (Bucheuma
spinosum) that induces hindpaw oedema. Carragee-
nan-induced oedema involves predominantly the
mediation of cyclooxygenase products of acid
arachidonate and this oedema is suppressed by all
nonsteroidal anti-inflammatory drugs (NSAIDS).
2
Although this model system bears little relation to
human disease conditions, it has significant
predictive value for clinically useful anti-infl-
ammatory agents.
3-5 However, there is controversy
about the effects of these drugs on the response to
carrageenan. For example, compounds of gold, the
most efficacious drugs for rheumatoid arthritis,
have absolutely no effect on carrageenan-induced
oedema.
6 Therefore, the search for novel model
systems continues in the development of new
anti-inflammatory drugs.
The present paper describes the oedemagenic
potential of Pilocarpus spicatus essential oil (PSEO)
in the hindpaw of rat and the mediator substances
involved in its action.
Materials and Methods
Animals: Male Wistar rats (120-180 g), housed at 25
-27C and maintained on standard pellet diet
(Purina Chow) and water ad libitum, were randomly
assigned to various treatment groups. Six animals
were included in each group.
Drugs and chemicals: The essential oil of P. spicatus was
supplied by the Natural Products Laboratory of the
Federal University of Ceart, Fortaleza, Brazil
and lambda carrageenan was purchased from Sigma
Chemical Company, St Louis, USA. The other
drugs were chlorpheniramine (Schering, So
Paulo, Brazil), dexamethasone (Upjohn, So Paulo,
Brazil), EP 10161 (Institut Henri Beaufour,
Le Plessis, France), phenylbutazone (Geigy, Sgo
Paulo, Brazil) and methysergide (Sandoz, So
Paulo, Brazil). PSEO was emulsified in Tween 80
(9:1 w/w) and diluted with 154 mM saline. EP
10161 was suspended in 5% DMSO and all other
drugs were dissolved in 154 mM saline.
Paw oedema assay: Using unanaesthetized rats, PSEO
(2.5% and 5%) or carrageenan (1%) was injected
into the subplantar surface of the right hindpaw in
a volume of 0.1 ml/rat. An equal volume of vehicle
was injected into the contralateral paw. The
volumes of both hindpaws up to the ankle joint
were measured with a plethysmometer prior to and
at different periods (1 h, 2 h, 3 h, 4 h, 5 h and 24 h)
after induction of oedema. The difference in the
volume between the hindpaws was a measure of the
oedema present (ml).
Inhibition of oedema by drugs: Unanaesthetized rats that
had been fasted overnight were treated with a single
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dose of chlorpheniramine (10 mg/kg, i.p.), methy-
sergide (lmg/kg, p.o.), phenylbutazone (100
mg/kg, p.o.), EP 10161 (20mg/kg, i.p.), dex-
amethasone (0.5 mg/kg, i.p.) or 154 mM saline
(2 ml/kg, i.p.). One hour after drug administration,
animals were given 0.1 ml of 5% PSEO into the
subplantar region of the right hindpaw. An equal
volume of vehicle was injected into the contralateral
paw. The paw volume measurements were carried
out as described earlier by a plethysmometer at
different periods following PSEO injection. The
mean paw oedema values for each drug treatment
were established and compared with vehicle-treated
control. The data were evaluated by use of
ANOVA and t-independent test. Statistical signifi-
cance was assigned for p < 0.05.
Results
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FIG. 2. Effects of drug pretreatment on the time course of rat hindpaw
oedema induced by subplantar injection of 5 mg PSEO. Vehicle control
(@)" chlorpheniramine, 10mg/kg, i.p. (/k); methysergide, mg/kg,
p.o. ([-3)" phenylbutazone, 100 mg/kg, p.o. ()" EP 10161, 20 mg/kg,
i.p. ()" and dexamethasone, 1.5mg/kg, i.p. (O). Drugs were
administered h before the subplantar injection of PSEO. Means SE
of data from six animals. *p < 0.05.
The effect of graded doses of PSEO (2.5 and
5 mg) and carrageenan (1 mg) on the magnitude of
hindpaw oedema is shown in Figure 1. Subplantar
injection of PSEO induced a dose-related elevation
of paw oedema at all time points. The oedemagenic
effect of 5 mg PSEO was greater than that of
carrageenan at 1 h post-injection, attained the same
peak level at 3 h, remained relatively constant up to
5 h and was still pronounced (almost 50% of peak
level) at 24 h.
Figure 2 shows the ability of some of the test
drugs to inhibit the oedema induced by 5 mg of
PSEO. The PSEO-induced rat hindpaw oedema
was not affected by chlorpheniramine, while paw
swelling that occurred at 1 h and 2h was
significantly reduced by methysergide. Methy-
sergide was not effective at all other time points.
The oedema caused by PSEO was also suppressed
by phenylbutazone, EP 10161 and dexamathasone.
At the peak effect of PSEO, the extent of oedema
inhibition was 25%, 41% and 65% for phenylbuta-
zone, EP 10161 and dexamethasone, respectively.
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FIG. 1. Time course of oedema after subplantar injection of PSEO and
carrageenan in rat. PSEO, 2.5mg (C)" PSEO, 5.0mg (O)’ and
carrageenan, mg (A). Means -t- SE of data from six animals.
At 24h, dexamethasone almost abolished the
oedema (98% inhibition), while EP 10161 showed
23% inhibition. Phenylbutazone had no significant
effect at this time.
Discussion
The results of the present study show that PSEO
is highly potent in promoting a local oedematous
reaction. This reaction is dose-dependent and has a
time course of action very similar to the one we
obtained with carrageenan. The action of PSEO,
however, seems more potent because it demon-
strated a greater magnitude of oedema than
carrageenan at 1 h and 2 h post-injection.
In order to characterize the oedema response to
PSEO, a number of specific pharmacological
antagonists were utilized. Pretreatment with the
H-receptor antagonist chlorpheniramine was with-
out any effect on PSEO response, while methy-
sergide, a serotonin antagonist significantly in-
hibited the response at an earlier time. This
observation suggested a possible injury to dermal
mast cells and release of serotonin in the early phase
of oedematous reaction. In agreement with the
results are the reports by others that serotonin but
not histamine is largely responsible for hindpaw
oedema induced by compound 48/80 and carragee-
nan. 1’7 Cyclooxygenase inhibition does not seem to
affect serotonin-induced paw oedema in rats and
probably for this reason phenylbutazone did not
show any influence on early phase oedema reaction
to PSEO. Nevertheless, the finding that phenylbu-
tazone, EP 10161 and dexamethasone (cycloox-
ygenase, lypoxygenase and phospholipase a2
inhibitors, respectively) were potent in suppressing
late phase oedema response to PSEO established
that eicosanoids are the major inflammatory
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mediators. The rank order potency of these
inhibitor drugs is dexamethasone > EP 10161 >
phenylbutazone. The fact that EP 10161 produces
a greater inhibitory effect than phenylbutazone
indicates that leukotrienes are more important
mediators than prostaglandins in this model. In
contrast, carrageenan-induced oedema involves
predominantly the mediation of prostaglandins.
In the present study, dexamethasone produced a
more potent block in the oedemagenic effect of
PSEO. Dexamethasone has been reported to inhibit
increased vascular permeability independent from
inhibition of phospholipase A2 .9 It is possible
that similar mechanisms might underlie the
inhibitory action of dexamethasone against PSEO-
induced inflammatory response.
The two major constituents of PSEO were
methylnonylketone ( 80%) and methylundecylke-
tone (10%). The oil also contains some
minor constituents such as terpenes and phenols. It
remains to be verified whether one or more of these
constituents are responsible for the induction of
PSEO-induced inflammatory reaction. It is prob-
able that PSEO, besides promoting mast cells
degranulation, may activate phospholipase A2
enzyme in vascular endothelial cells and may release
arachidonic acid from membrane phospholipids.
Arachidonate metabolism through cyclooxygenase
and lipoxygenase pathways is known to produce
highly potent inflammatory mediators, namely
prostaglandins, thromboxanes and leukotrienes.
10-12
Therefore it is reasonable to assume that PSEO-
induced hindpaw oedema in rat involves serotonin
at the early phase and eicosanoids, particularly
leukotrienes, at the late phase.
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